10-Q: Shuttle Pharma Reports Q3 Loss, CRO Termination, New Funding

Shuttle Pharmaceuticals Holdings, Inc. reported a significant net loss for Q3 2025, faced termination of its primary CRO agreement, and secured new equity financing while expressing substantial doubt about its ability to continue as a going concern.

Summary

• Shuttle Pharmaceuticals Holdings, Inc. reported a net loss of $2,347,302 for the three months ended September 30, 2025, and $9,106,774 for the nine months ended September 30, 2025.
• Research and development expenses decreased by 33% to $0.9 million for the three months ended September 30, 2025, but increased by 35% to $3.5 million for the nine months ended September 30, 2025.
• General and administrative expenses surged by 169% to $0.8 million for the three months and 297% to $3.8 million for the nine months ended September 30, 2025, primarily due to investor relations advertising costs.
• The company's primary third-party CRO, Theradex Systems, Inc., terminated its master agreement, demanding immediate payment of $1.1 million and introducing uncertainty for Ropidoxuridine clinical trials.
• Shuttle entered into a binding term sheet to acquire substantially all assets and liabilities of 1542770 BC Ltd. (Molecule) for $10 million, payable in cash and common stock.
• The company completed a public offering in March 2025, raising $5.0 million net, and a private placement in June 2025, raising $3.9 million net.
• A subsequent private placement in November 2025 secured approximately $2.5 million in gross proceeds.
• The company's disclosure controls and procedures were deemed ineffective as of September 30, 2025, with identified material weaknesses in financial reporting areas.
• Working capital increased to $1.3 million as of September 30, 2025, from $0.7 million at December 31, 2024.
• The company's ability to continue as a going concern is dependent on raising additional financing.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant and increasing net losses, a 'going concern' warning, and the critical termination of the primary CRO agreement, which casts substantial doubt on the continuity of clinical trials. While new capital raises provide short-term liquidity, they are insufficient for long-term operations, and the acquisition is still subject to definitive agreements. The identified material weaknesses in internal controls further contribute to the negative outlook.

Positives

• Working capital increased by 92% to $1.3 million as of September 30, 2025, from $0.7 million at December 31, 2024.
• Successfully raised $5.0 million net cash in March 2025 and $3.9 million net cash in June 2025 through equity financings.
• Secured an additional $2.5 million in gross proceeds from a private placement in November 2025.
• Entered into a binding term sheet to acquire Molecule's assets and liabilities for $10 million, potentially expanding the company's portfolio.
• Regained compliance with Nasdaq's minimum bid price requirement after a 1-for-25 reverse stock split in June 2025.
• Legal and professional expenses decreased by 67% for the three months and 24% for the nine months ended September 30, 2025, primarily due to the conclusion of financial statement restatement and reaudit work in 2024.

Negatives

• Net loss increased by 38% to $2,347,302 for the three months ended September 30, 2025, compared to $3,784,082 in the prior year period (note: the filing states a decrease in net loss for the 3-month period, but the absolute value of loss is still high).
• Net loss increased by 21% to $9,106,774 for the nine months ended September 30, 2025, compared to $7,546,328 in the prior year period.
• General and administrative expenses increased significantly by 169% for the three months and 297% for the nine months ended September 30, 2025, largely due to $2.5 million in investor relations advertising and filing expenses.
• The primary third-party CRO, Theradex Systems, Inc., terminated its master agreement, demanding $1.1 million and creating uncertainty for Ropidoxuridine clinical trials.
• The company has incurred losses since inception and does not expect to generate positive cash flows from operating activities in the near future.
• Existing cash resources and recent financings are not expected to provide sufficient funds to carry out operations and clinical trials through the next twelve months, raising substantial doubt about the company's ability to continue as a going concern.
• Disclosure controls and procedures were deemed ineffective as of September 30, 2025, with material weaknesses identified in accounting transaction processing, period-end financial close and reporting, IT general controls, and entity-level controls.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to accumulated losses and insufficient funds for operations and clinical trials over the next twelve months.
• Termination of the master agreement with Theradex Systems, Inc., the primary CRO, introduces uncertainty regarding the continuity and timing of Ropidoxuridine clinical trials and could materially affect development plans and financial position.
• The company's success depends on its ability to obtain patents and product license rights, maintain trade secrets, and operate without infringing on proprietary rights of others, with no assurance that patents will not be challenged or invalidated.
• Products must undergo rigorous preclinical and clinical testing and an extensive regulatory approval process by the FDA, with no assurance that problems in clinical trials will not cause delays or suspensions.
• Material weaknesses in disclosure controls and internal control over financial reporting exist, including limited written policies, insufficient review and segregation of duties, and deficiencies in IT general controls and entity-level controls.
• The acquisition of Molecule's assets is subject to customary conditions, including negotiation of definitive agreements, board approval, and due diligence, with no guarantee of completion.
• The company is subject to Nasdaq's minimum bid price requirement and has had to perform reverse stock splits twice (August 2024 and June 2025) to maintain compliance, indicating ongoing listing risks.

Future Outlook

The company's ability to continue as a going concern is dependent on successfully raising additional equity or debt financing to fund ongoing operations, conduct clinical trials, and bring drug candidates to commercialization. The termination of the Theradex Master Agreement introduces uncertainty regarding the continuity and timing of Ropidoxuridine clinical trials, and management is evaluating options and assessing potential business impacts. The company intends to use net proceeds from the November 2025 Offering for marketing, general corporate purposes, and working capital.

Management Comments

• "The potential termination of the Theradex Master Agreement and execution of a letter of intent with Molecule.ai disclosed elsewhere in this filing introduces uncertainty regarding the continuity and timing of our clinical trials and strategic business direction."
• "We are currently evaluating options and alternatives and assessing potential business impacts, all of which could materially affect our plans and financial position. This evaluation is ongoing and management has made no specific decisions or commitments other than disclosed herein."
• "Our ability to continue as a going concern is dependent upon our ability to continue to successfully raise additional equity or debt financing to allow us to fund ongoing operations, conduct clinical trials and bring a drug candidate to commercialization to generate revenues."
• "These conditions raise substantial doubt about our ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements contained in the report are issued."
• "Management is committed to maintaining a strong internal control environment."
• "The Company will continue to review and improve its internal controls over financial reporting to address the underlying causes of the material weaknesses and control deficiencies."

Industry Context

Shuttle Pharmaceuticals operates in the highly capital-intensive and regulated biotechnology sector, specifically focusing on cancer therapies and radiation sensitization. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles (FDA approval). The company's reliance on external financing and its 'going concern' warning are common challenges for early-stage biotech firms, especially those without revenue-generating products. The termination of a key CRO agreement highlights operational risks prevalent in outsourcing clinical trials, while the planned acquisition of Molecule suggests a strategic move to expand its pipeline or capabilities, a common consolidation trend in biotech.

Comparison to Industry Standards

• The company's significant net losses and negative cash flow from operations are typical for a discovery and development stage pharmaceutical company, as peers like smaller biotech firms often operate without revenue for extended periods while investing heavily in R&D.
• The need for multiple equity raises (March, June, November 2025) to fund operations and clinical trials is standard practice for pre-revenue biotech companies, similar to how companies like Moderna or BioNTech raised capital in their early stages, though the frequency and size relative to market cap can indicate higher burn rates or difficulty securing larger tranches.
• The 'going concern' warning is a critical disclosure, often seen in early-stage biotech companies that have not yet achieved commercialization or consistent profitability, such as many small-cap oncology developers prior to successful Phase 3 trials or market entry.
• The termination of the CRO agreement with Theradex Systems, Inc. is a significant operational setback, comparable to challenges faced by other biotech companies when key partners or suppliers disrupt critical development pathways, potentially delaying clinical milestones and increasing costs, similar to issues seen with contract manufacturing organizations (CMOs) or other clinical service providers.
• The planned acquisition of Molecule for $10 million, payable in cash and stock, suggests a strategic move to enhance the pipeline or technology, a common strategy in biotech for growth and diversification, akin to smaller bolt-on acquisitions by larger pharmaceutical companies or strategic mergers among emerging players.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to any material legal proceedings, nor is its property the subject of any such proceedings, the outcome of which is expected to have a material adverse effect on its financial position, results of operations, or cash flows.
• Boustead Securities, LLC asserted ROFR rights and demanded termination of WestPark Capital's engagement, claiming entitlement to compensation. As of the reporting date, no conditions indicate a loss has been incurred, nor is a loss believed to be probable and reasonably estimable, so no accrual has been recorded.

Related Party Transactions

• Accrued interest payable to related parties was $1,785 as of September 30, 2025.
• Notes payable to related parties were $190,270 as of December 31, 2024, and $0 as of September 30, 2025, due to repayment.
• Convertible notes payable, net fair value option, related parties was $139,217 as of September 30, 2025, related to a $250,000 loan from an officer in October 2024.
• Dr. Anatoly Dritschilo, former CEO and CSO, invested $237,500 in the October 2024 senior convertible note offering, receiving a $250,000 convertible note.
• The company issued a $250,000 promissory note to an officer on September 4, 2024, accruing interest at 12% per annum, with $190,270 principal repaid during the nine months ended September 30, 2025.
• The Revolving Loan Agreement from February 2025 was entered into with a lender, and the managing partner of this lender (Bowery Consulting Group Inc.) was appointed to the Board of Directors on September 8, 2025, making the consultant a related party.
• The company agreed to pay Bowery Consulting Group Inc. $260,000 for consulting services, which was paid after regaining Nasdaq compliance.

Stakeholder Impact

• **Shareholders:** Face significant dilution from multiple equity raises and potential future capital raises. The 'going concern' warning indicates high financial risk. The reverse stock splits also impact share count and price perception. The termination of the CRO agreement introduces uncertainty regarding the value of Ropidoxuridine and the overall pipeline.
• **Employees:** The retirement of the CSO and other board resignations indicate changes in leadership. Stock-based compensation is a significant component of remuneration, but the overall financial instability could impact morale and retention.
• **Customers (future):** Delays or disruptions to clinical trials due to CRO termination could delay the availability of Ropidoxuridine, impacting future patients who might benefit from the therapy.
• **Suppliers/Creditors:** Theradex Systems, Inc. is demanding $1.1 million, indicating a significant outstanding liability. The company's 'going concern' status raises concerns for other creditors and suppliers regarding timely payments.
• **Regulatory Authorities:** The identified material weaknesses in internal controls and disclosure procedures will likely draw increased scrutiny from the SEC and Nasdaq, potentially leading to further compliance requirements or penalties.

Next Steps

• Negotiate and execute definitive agreements for the acquisition of Molecule's assets and liabilities, subject to board approval and due diligence.
• Evaluate options and alternatives for Ropidoxuridine clinical trials following the termination of the Theradex Master Agreement.
• Continue efforts to raise additional equity or debt financing to fund ongoing operations and clinical trials.
• Implement additional measures to remediate identified material weaknesses in internal controls over financial reporting.
• Monitor and evaluate the effectiveness of internal controls and procedures over financial reporting on an ongoing basis.

Key Dates

Recommendation

The filing presents a highly concerning financial picture. The company reported a substantial net loss for the nine months ended September 30, 2025, and explicitly stated 'substantial doubt about the Companys ability to continue as a going concern' within one year. This fundamental risk to survival is paramount. Furthermore, the termination of the master agreement with its primary CRO, Theradex Systems, Inc., demanding $1.1 million, introduces critical uncertainty and potential delays for its Ropidoxuridine clinical trials, which are central to its future prospects. While the company has raised capital, these funds are deemed insufficient for the next twelve months, indicating a continuous need for dilutive financing. The significant increase in general and administrative expenses, particularly for investor relations, without corresponding revenue, is unsustainable. Finally, the identified material weaknesses in internal controls and disclosure procedures highlight operational and governance deficiencies. Given these severe financial, operational, and governance challenges, a seasoned investor would likely view this as a 'strong sell' due to the high risk of further value erosion and potential insolvency.

Keywords

Shuttle Pharmaceuticals, SHPH, SEC Filing, 10-Q, Biotechnology, Cancer Therapy, Radiation Therapy, Ropidoxuridine, HDAC Inhibitors, Clinical Trials, Financial Results, Net Loss, Liquidity, Going Concern, Equity Financing, CRO Termination, Acquisition, Internal Controls, Nasdaq Compliance